A team of researchers developed 3 quality improvement measures embedded in electronic health records (EHRs) to improve care delivery in patients with heparin-induced thrombocytopenia. HIT is known as ...

Sponsored by: Diagnostica Stago, Inc. The first step in thwarting devastating complications is to maintain a high index of clinical suspicion by an accurate clinical scoring assessment using the 4T’s ...

Novel first-in-class therapeutic targeting a key immune signaling pathway and the underlying cause of HIT It is the first and only potent, highly selective inhibitor of human 12-LOX in clinical ...

Purpose: A case of heparin-induced thrombocytopenia (HIT) complicated by warfarin-induced skin necrosis (WISN) is reported. Summary: A patient with a history of hypertension, heart failure, and ...

Heparin-induced thrombocytopenia (HIT) is an immune-mediated platelet disorder caused by antibodies that target complexes of platelet factor 4 (PF4) and heparin. HIT has been characterized as a ...

Please provide your email address to receive an email when new articles are posted on . A phase 1A study consisted of a single ascending dose portion and a multiple ascending dose portion designed to ...

Credit: Getty Images. VLX-1005 is a first-in-class, selective small molecule inhibitor of 12-lipoxygenase, a key target within the arachidonic acid pathway. The Food and Drug Administration (FDA) has ...

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Spontaneous heparin-induced thrombocytopenia is a pro-thrombotic syndrome in which anti-heparin antibodies ...

Cadrenal Therapeutics (CVKD) acquired VLX-1005 and related 12-lipoxygenase assets from Veralox Therapeutics. The acquisition adds a late-stage, ...

TCT 378: Contemporary Analysis and Outcomes of Orbital Atherectomy (OA) and Rotational Atherectomy (RA) for Inpatient Percutaneous Coronary Intervention (PCI) Receive the the latest news, research, ...